Try our mobile app

TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting

Published: 2020-12-07 15:15:00 ET
<<<  go to TGTX company page

UNITY-CLL: U2 significantly improved progression-free survival over obinutuzumabplus chlorambucil (HR=0.54, p